Friday 06 Jun, 2025 06:30 PM
Site map | Locate Us | Login
   Muthoot Finance jumps 18% in six days    Azad Engineering Ltd leads losers in 'A' group    KPI Green gains after arm inks three strategic MoUs with Delta Electronics    Privi Speciality Chemicals Ltd leads losers in 'B' group    Volumes soar at Ramkrishna Forgings Ltd counter    IndusInd Bank climbs as RBI sees turbulence easing    JSW Energy expands renewable capacity by 281 MW with new solar & wind projects    Capital Goods stocks edge lower    HDFC Bank Ltd soars 1.44%, rises for third straight session    Gujarat Gas Ltd soars 0.39%, gains for fifth straight session    Nila Spaces gains as arm awards construction contract to Riveria Infrastructures    Hybrid Financial Services Ltd leads gainers in 'B' group    Ramkrishna Forgings Ltd leads gainers in 'A' group    Max Estates gains after board approves related party transaction with ASLL    Hawkins Cookers' fourth factory in Uttar Pradesh commences commercial production 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Dr Reddys Lab gains on global biosimilar deal with Alvotech
05-Jun-25   10:10 Hrs IST

Keytruda, a widely used immunotherapy for various cancer types, recorded global sales of $29.5 billion in 2024. The partnership involves joint development and manufacturing of the biosimilar, with both companies sharing costs and responsibilities. Subject to certain conditions, both parties will also have rights to commercialize the product worldwide.

Alvotech, a biotech company focused on biosimilars, already has two approved biosimilars, adalimumab and ustekinumab, marketed in several countries. It has a strong pipeline of nine additional biosimilars and a global network of commercial partnerships spanning the US, Europe, Asia, Latin America, and Africa.

Dr. Reddy's Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.

On a consolidated basis, net profit of Dr Reddy's Laboratories rose 21.64% to Rs 1593.30 crore while net sales rose 20.09% to Rs 8506 crore in Q4 March 2025 over Q4 March 2024.

Powered by Capital Market - Live News
   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Investor Charter | Annual Return | Account Closure | RE-KYC | Disclaimer | Feed Back | Privacy Policy | Policies & Procedures | Rights & Obligations-English | (Rights & Obligations, Risk Disclosure Document, Do's & Don't's) in Vernacular Language | Anti Money Laundering Policy | E-Voting | CSR | Voluntary Freezing / Blocking | Policy GTC | Policy On Inactive Trading Accounts | Risk Disclosure Hit Count : 41378114
Useful Links : NSE | BSE | MCX | NSDL | CDSL | SEBI | RBI | ATTENTION INVESTOR| SMART ODR
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL Securities Private Limited